Ospomyv

Active Ingredient(s): Denosumab-dssb
FDA Approved: * February 13, 2025
Pharm Company: * SAMSUNG BIOEPIS CO LTD
Category: Osteoporosis

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.[1][2] Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.[3] Denosumab is a inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand),[1&... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients